Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding 11 year track record as a NYSE listed company with an approximate $5.2 billion total market capitalization (as of December 31, 2008).
Recent Milestones
Investments
Videos
Sources
-
Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities (businesswire.com)
[edit]
-
Theraclone Sciences Closes $14M in Series B and Debt Financing (finsmes.com)
[edit]
-
Oncofactor, Inc.: Series A $2.1M (onbiovc.com)
[edit]
-
Acylin Therapeutics, Inc.: Series A $4.4M (onbiovc.com)
[edit]
-
Mirina Nabs $3.9M (xconomy.com)
[edit]
-
Theraclone Raises $1.5M (xconomy.com)
[edit]
-
Metabolon, Inc.: Series C $6M (onbiovc.com)
[edit]
-
Cambrios lands $14.5M for electronic display components (deals.venturebeat.com)
[edit]
-
BrainCells Secures $20 Million More Series B Funding (venturedeal.com)
[edit]
-
Tempo Pharmaceuticals Closes $8 Million in Series B Funding (ceruleanrx.com)
[edit]
-
Allozyne, Inc., Closes $30 Million Series B Financing (allbusiness.com)
[edit]
-
Nutmeg State biotech lands $25.8M in round one (masshightech.com)
[edit]
-
EDGAR
[edit]